Key points
- Total revenue and other income decreased by 45% to $77,667.
- Loss before income tax expense increased by 101% to $(3,095,190).
- Net loss after tax increased by 238% to $(2,710,723).
- No dividends were paid during the financial period.
- Algorae expanded into pharmaceutical commercialisation through AlgoraeRx.
Full summary
Algorae Pharmaceuticals Limited reported a 45% decrease in total revenue and other income to $77,667 for the year ended 30 June 2026, compared to the previous year. The company also reported a 101% increase in loss before income tax expense to $(3,095,190) and a 238% increase in net loss after tax to $(2,710,723). The increase in losses was primarily due to higher operating expenses, share-based payments, and a decrease in R&D tax refunds. The company did not pay any dividends during the financial period. Algorae expanded its operations by entering into pharmaceutical commercialisation through its subsidiary, AlgoraeRx, which executed licensing and supply agreements with international pharmaceutical manufacturers. The company also launched version 2 of its AI drug-combination discovery platform, AlgoraeOS, and achieved the first independent preclinical validation of the platform's predictions.